Hua Medicine (Shanghai) Ltd.

Clinical stage drug development in China for Type 2 Diabetes

Hua Medicine is a clinical stage innovative drug development company founded in 2011 in China and focused on novel therapies for the treatment of diabetes. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. The company went public on the Hong Kong Stock Exchange in September of 2018 and trades under he code -- HKG: 02552.